American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term efficacy and safety of elranatamab monotherapy in the phase 2 magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM)
    Meeting Abstract

    Tomasson, M.; Iida, S.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Martinez-Lopez, J.; Koehne, G.; Otero, P. R.; Prince, H. M.; Viqueira, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) with missing molecular data
    Meeting Abstract

    Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A first-in-human phase 1 trial of NX-2127, a first-in-class Bruton's tyrosine kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed/refractory B cell malignancies
    Meeting Abstract

    Danilov, A.; Tees, M. T.; Patel, K.; Wierda, W. G.; Patel, M.; Flinn, I. W.; Latif, T.; Ai, W. Y.; Thompson, M. C.; Wang, M. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Updated results of the phase I BALLI-01 trial of UCART22 Process 2 (P2), an anti-CD22 allogeneic CAR-T cell product manufactured by Cellectis Biologics, in patients with relapsed or refractory (R/R) CD22+ B-cell acute lymphoblastic leukemia (B-ALL)
    Meeting Abstract

    Jain, N.; Chevallier, P.; Liu, H. T.; Schiller, G. J.; Méar, J. B.; DeAngelo, D. J.; Curran, K. J.; Grupp, S.; Baruchel, A.; Balsat, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • KB-Lanra 1001: A phase 1b/2 study of safety, PK, PD, and preliminary efficacy of the selective SYK inhibitor lanraplenib in combination with the FLT3 inhibitor gilteritinib in FLT3-mutated R/R AML
    Meeting Abstract

    Arnan, M.; Patel, A. A.; Esteve, J.; Morris, L.; Schiller, G. J.; Swords, R. T.; Alonso-Dominguez, J. M.; Michaelis, L. C.; Daver, N.; Carvajal, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Artificial intelligence and venous thromboembolism: Talking to the experts
    Meeting Abstract

    Gupta, A.; Lam, B. D.; Zerbey, S.; Robertson, W.; Rosovsky, R. P.; Lake, L.; Dodge, L.; Adamski, A.; Reyes, N.; Abe, K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Post allogeneic stem cell transplant outcomes following response to hypomethylating agent therapy in myelodysplastic syndromes are predicted by persistent international prognostic scoring system-molecular risk
    Meeting Abstract

    Frumm, S. M.; Kim, H. T.; Kelkar, A. H.; Ho, V. T.; Gooptu, M.; Gibson, C. J.; Koreth, J.; Shapiro, R. M.; Romee, R.; Nikiforow, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Selinexor, ixazomib, pomalidomide and dexamethasone in functionally high-risk multiple myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) sub-protocol Y3
    Meeting Abstract

    Richter, J.; Zonder, J. A.; Nathwani, N.; Bianchi, G.; Hofmeister, C. C.; Vij, R.; Pianko, M.; Kaur, G.; Hultcrantz, M.; Wozniak, K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Validation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) who were treated with hypomethylating agents (HMA)
    Meeting Abstract

    Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Beat AML S8 Group 2: Gilteritinib (GILT) in combination with decitabine (DEC) and venetoclax (VEN) in untreated FLT3 mutated acute myeloid leukemia (AML) patients age ≥60 with high and low variant allele frequency (VAF)
    Meeting Abstract

    Liu, Q.; Welkie, R. L.; Huang, Y.; Swords, R. T.; Lin, T. L.; Koenig, K. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; Blum, W.; more...
    Blood (2023)

    Fulltext@MSK | Save